| 國家衛生研究院 |
2006-05 |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'ang, HJ; Wang, CC; Cheng, AL; Hsu, C; Lu, YS; Chang, MC; Lin, JT; Wang, HP; Shiah, HS; Liu, TW; Chang, JY; Whang-Peng, J; Chen, LT |
| 臺大學術典藏 |
2022-08-19T00:21:12Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; CHIUN HSU; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T02:02:13Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'ang H.-J.; Wang C.-C.; ANN-LII CHENG; Hsu C.; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-03-05T06:07:34Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Hsu C.; Lu Y.-S.; MING-CHU CHANG; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 高雄醫學大學 |
2006 |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
鄭安理;林肇堂;劉滄梧;彭汪嘉康;陳立宗 ; Chang HJ;Wang CC;Cheng AL;Hsu C;Lu YS;Chang MC;Lin JT;Wang HP;Shiah HS;Liu TW;Chang JY;Whang-Peng J;Chen LT |
| 國家衛生研究院 |
2012-02 |
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on firstline oxaliplatin-based chemotherapy
|
Chen, LT;Shiah, HS;Lin, PC;Lee, JC;Su, WC;Wang, YW;Yeh, G;Chang, JY |
| 國立臺灣大學 |
2009 |
Phase I Study of Cetuximab, Erlotinib, and Bevacizumab in Patients with Advanced Solid Tumors
|
林家齊; LIN, CHIA-CHI |
| 臺大學術典藏 |
2009 |
Phase i study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
|
Tolcher A.W.; Chen H; Dancey J.E; Takimoto C.H; O'Rourke P; Yeh I.-T; Chia-Chi Lin; Calvo E; Papadopoulos K.P; Patnaik A; Sarantopoulos J; Mita A.C; Preston G.G; Mita M.M; Rodon J; Mays T |
| 國立臺北護理健康大學 |
1990 |
Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies.
|
Hu, E;Watkins, K;Groshen, S;Chen, SC;Malloy, B;Agah, R;Nichols, P;Parker, J;Martin, A;Boosalis, MG |
| 臺大學術典藏 |
2013 |
Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma
|
Lopez-Martin J.A; Chia-Chi Lin; Gschwend J.E; Harzstark A; Castellano D; Soria J.-C; Sen P; Chang J; Shi M; Kay A; Escudier B.; Angevin E |
| 國家衛生研究院 |
2021-05 |
Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)
|
Macarulla, T;Moreno, V;Chen, LT;Sawyer, MB;Goyal, L;Martin, AJM;Sheng-Shun, Y;Le Sourd, S;Morris, J;Fuchs, M;Karasic, TB;Kang, YK;Yong, WP;Selvaraj, A;Destenaves, B;Xiao, JA;Gomez, R;Gualberto, A;Pipas, JMM;Finn, RS |
| 國家衛生研究院 |
2010-05 |
Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors
|
Chen, L;Shiah, H;Chao, T;Hsieh, RK;Chen, G;Chang, J;Yeh, G |
| 國家衛生研究院 |
2015-03 |
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
|
Chang, TC;Shiah, HS;Yang, CH;Yeh, KH;Cheng, AL;Shen, BN;Wang, YW;Yeh, CG;Chiang, NJ;Chang, JY;Chen, LT |
| 國立成功大學 |
2015-03 |
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
|
Chang, T. C.; Shiah, H. S.; Yang, C. H.; Yeh, K. H.; Cheng, A. L.; Shen, B. N.; Wang, Y. W.; Yeh, C. G.; Chiang, N. J.; Chang, J. Y.; Chen, L. T. |
| 臺大學術典藏 |
2018-09-10T15:17:40Z |
Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
|
Chang, T.C. and Shiah, H.S. and Yang, C.H. and Yeh, K.H. and Cheng, A.L. and Shen, B.N. and Wang, Y.W. and Yeh, C.G. and Chiang, N.J. and Chang, J.Y. and Chen, L.T.; KUN-HUEI YEH; ANN-LII CHENG |
| 臺大學術典藏 |
2020-05-26T09:26:56Z |
Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
|
Chen L.T.;Chang J.Y;Chiang N.J;Yeh C.G;Wang Y.W;Shen B.N;Cheng A.L;Yeh K.H;Chih-Hsin Yang;Shiah H.S;Chang T.C; Chang T.C; Shiah H.S; CHIH-HSIN YANG; Yeh K.H; Cheng A.L; Shen B.N; Wang Y.W; Yeh C.G; Chiang N.J; Chang J.Y; Chen L.T. |
| 臺大學術典藏 |
2021-01-28T01:06:31Z |
Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
|
Chang T.C.; Shiah H.S.; Yang C.H.; KUN-HUEI YEH; Cheng A.L.; Shen B.N.; Wang Y.W.; Yeh C.G.; Chiang N.J.; Chang J.Y.; Chen L.T. |
| 臺大學術典藏 |
2021-08-31T06:42:20Z |
Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
|
Chang T.C.; Shiah H.S.; Yang C.H.; Yeh K.H.; ANN-LII CHENG; Shen B.N.; Wang Y.W.; Yeh C.G.; Chiang N.J.; Chang J.Y.; Chen L.T. |
| 國立臺灣大學 |
2009 |
Phase I Study of Pazopanib (Paz) in Hepatocellular Carcinoma (Hcc): Determination of Mtd and Evaluation of Clinical Activity, Pharmacokinetics (Pk), and Pharmacodynamic (Pd) Changes in Dynamic Contrast Enhanced Mri ( Dce-Mri)
|
陳培哲; CHEN, PEI-JER |
| 國立臺灣大學 |
2009 |
Phase I Study of Pazopanib (Paz) in Hepatocellular Carcinoma (Hcc): Evaluation of Clinical Activity, Pharmacokinetics (Pk), and Dynamic Contrast Enhanced Mri (Dce-Mri)
|
陳培哲; CHEN, PEI-JER |
| 臺大學術典藏 |
2021-04-23T05:56:25Z |
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non�Vsmall Cell Lung Cancer
|
Yu H.A.;Paz-Ares L.G.;Chih-Hsin Yang;Lee K.H.;Garrido P.;Park K.;Kim J.-H.;Lee D.H.;Mao H.;Wijayawardana S.R.;Gao L.;Hozak R.R.;Chao B.H.;Planchard D.; Yu H.A.; Paz-Ares L.G.; CHIH-HSIN YANG; Lee K.H.; Garrido P.; Park K.; Kim J.-H.; Lee D.H.; Mao H.; Wijayawardana S.R.; Gao L.; Hozak R.R.; Chao B.H.; Planchard D. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Chia-Chi Lin;Takeuchi Y;Pronk L.C;Sarashina A;Cheng A.-L;Naito Y;Shitara K;Yang J.C.-H;Doi T; Doi T; Yang J.C.-H; Shitara K; Naito Y; Cheng A.-L; Sarashina A; Pronk L.C; Takeuchi Y; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T;Chih-Hsin Yang;Shitara K;Naito Y;Cheng A.-L;Sarashina A;Pronk L.C;Takeuchi Y;Lin C.-C.; Doi T; CHIH-HSIN YANG; Shitara K; Naito Y; Cheng A.-L; Sarashina A; Pronk L.C; Takeuchi Y; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T.; Yang J.C.-H.; Shitara K.; Naito Y.; ANN-LII CHENG; Sarashina A.; Pronk L.C.; Takeuchi Y.; Lin C.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:08Z |
Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor �] (TGF-�]) and PD-L1
|
Chia-Chi Lin; Doi T; Muro K; Hou M.-M; Esaki T; Hara H; Chung H.-C; Osada M; Helwig C; Kondo S. |
